Baidu
map

急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版)

2019-01-30 国家卫生计生委合理用药专家委员会 《中国医学前沿杂志(电子版)》.2019,11(1):40-65.

为规范基层医院STEMI的溶栓救治流程,提高溶栓救治成功率,根据我国基层医院STEMI救治状况,结合国内外指南及共识,特别是我国基层STEMI溶栓治疗的相关经验,我们于2016年颁布了《急性ST段抬高型心肌梗死溶栓治疗的合理用药指南》,规范了基层医院STEMI患者的溶栓治疗流程,供基层医生在STEMI溶栓救治中参考,并取得了良好的效果。近2年,随着本指南的推广和普及,以及第三代特异性纤溶酶的广泛应

中文标题:

急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版)

发布日期:

2019-01-30

简要介绍:

为规范基层医院STEMI的溶栓救治流程,提高溶栓救治成功率,根据我国基层医院STEMI救治状况,结合国内外指南及共识,特别是我国基层STEMI溶栓治疗的相关经验,我们于2016年颁布了《急性ST段抬高型心肌梗死溶栓治疗的合理用药指南》,规范了基层医院STEMI患者的溶栓治疗流程,供基层医生在STEMI溶栓救治中参考,并取得了良好的效果。近2年,随着本指南的推广和普及,以及第三代特异性纤溶酶的广泛应用,相较于非选择性纤溶酶如尿激酶,静脉溶栓治疗的血管再通率明显提高,出血并发症发生率明显降低。2017年,欧洲心脏病学会(European Society of Cardiology,ESC)STEMI患者的管理指南表明,STEMI发病2 h内溶栓效果与直接PCI相当,且如不能在120 min内行直接PCI开通梗死血管,则推荐在10 min内静脉溶栓甚至院前溶栓。中国医师协会胸痛专业委员会和中国医学救援协会心血管急救分会新颁布的《ST段抬高型急性心肌梗死院前溶栓治疗中国专家共识》也推荐在积极肝素化抗凝的基础上进行院前溶栓。根据我国相关医疗卫生政策、胸痛中心建设的实践经验及专家、读者的反馈,我们组织了国内相关专家学者、胸痛中心救治医生以及基层医院一线救治人员,对本指南进行修订,使其更能体现国内外STEMI救治的理念进展和治疗规范,并结合我国实际情况,使之更加适用于我国STEMI的救治,为广大临床医生提供更为规范、详尽的指导。应强调的是,由于各地医疗条件、技术、救治水平不同,在使用本指南时可因时、因地制宜参考应用。 

拓展指南:心肌梗死相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版))] GetToolGuiderByIdResponse(projectId=1, id=295531c001e023b7, title=急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版), enTitle=, guiderFrom=《中国医学前沿杂志(电子版)》.2019,11(1):40-65., authorId=null, author=, summary=为规范基层医院STEMI的溶栓救治流程,提高溶栓救治成功率,根据我国基层医院STEMI救治状况,结合国内外指南及共识,特别是我国基层STEMI溶栓治疗的相关经验,我们于2016年颁布了《急性ST段抬高型心肌梗死溶栓治疗的合理用药指南》,规范了基层医院STEMI患者的溶栓治疗流程,供基层医生在STEMI溶栓救治中参考,并取得了良好的效果。近2年,随着本指南的推广和普及,以及第三代特异性纤溶酶的广泛应, cover=, journalId=null, articlesId=null, associationId=1325, associationName=国家卫生计生委合理用药专家委员会, associationIntro=, copyright=0, guiderPublishedTime=Wed Jan 30 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>为规范基层医院STEMI的溶栓救治流程,提高溶栓救治成功率,根据我国基层医院STEMI救治状况,结合国内外指南及共识,特别是我国基层STEMI溶栓治疗的相关经验,我们于2016年颁布了《急性ST段抬高型心肌梗死溶栓治疗的合理用药指南》,规范了基层医院STEMI患者的溶栓治疗流程,供基层医生在STEMI溶栓救治中参考,并取得了良好的效果。近2年,随着本指南的推广和普及,以及第三代特异性纤溶酶的广泛应用,相较于非选择性纤溶酶如尿激酶,静脉溶栓治疗的血管再通率明显提高,出血并发症发生率明显降低。2017年,欧洲心脏病学会(European Society of Cardiology,ESC)STEMI患者的管理指南表明,STEMI发病2 h内溶栓效果与直接PCI相当,且如不能在120 min内行直接PCI开通梗死血管,则推荐在10 min内静脉溶栓甚至院前溶栓。中国医师协会胸痛专业委员会和中国医学救援协会心血管急救分会新颁布的《ST段抬高型急性心肌梗死院前溶栓治疗中国专家共识》也推荐在积极肝素化抗凝的基础上进行院前溶栓。根据我国相关医疗卫生政策、胸痛中心建设的实践经验及专家、读者的反馈,我们组织了国内相关专家学者、胸痛中心救治医生以及基层医院一线救治人员,对本指南进行修订,使其更能体现国内外STEMI救治的理念进展和治疗规范,并结合我国实际情况,使之更加适用于我国STEMI的救治,为广大临床医生提供更为规范、详尽的指导。应强调的是,由于各地医疗条件、技术、救治水平不同,在使用本指南时可因时、因地制宜参考应用。 </div> <div><br> </div> 拓展指南:<strong>与<font color=red>心肌梗死</font>相关指南:</strong><br><ul><li><a href="//m.sandwebs.com/guideline/show_article.do?id=a0e5d1c00168612c" title="第四次心肌梗死全球统一定义(2018)要点解读:重视心肌损伤,细化心肌梗死诊断" target=_blank>第四次心肌梗死全球统一定义(2018)要点解读:重视心肌损伤,细化心肌梗死诊断</a></li> <li><a href="//m.sandwebs.com/guideline/show_article.do?id=308dc1c00163255b" title="2018 第四版心肌梗死通用定义" target=_blank>2018 第四版心肌梗死通用定义</a></li> <li><a href="//m.sandwebs.com/guideline/show_article.do?id=5cc351c00158a352" title="ST段抬高型急性心肌梗死院前溶栓治疗中国专家共识" target=_blank>ST段抬高型急性心肌梗死院前溶栓治疗中国专家共识</a></li> <li><a href="//m.sandwebs.com/guideline/show_article.do?id=503531c001526ec2" title="2017 ACEP临床决策:需要进行再灌注治疗的急性ST段抬高型心肌梗死患者的急诊管理" target=_blank>2017 ACEP临床决策:需要进行再灌注治疗的急性ST段抬高型心肌梗死患者的急诊管理</a></li> <li><a href="//m.sandwebs.com/guideline/show_article.do?id=e3c391c001511281" title="欧洲心脏病学会2017版急性ST段抬高型心肌梗死诊断和治疗指南更新之我见" target=_blank>欧洲心脏病学会2017版急性ST段抬高型心肌梗死诊断和治疗指南更新之我见</a></li> 更多信息请点击:<a href="//m.sandwebs.com/guideline/list.do?q=%E5%BF%83%E8%82%8C%E6%A2%97%E6%AD%BB" target=_blank>有关心肌梗死更多指南</a></ul>, tagList=[TagDto(tagId=6530, tagName=急性ST段抬高型心肌梗死), TagDto(tagId=3285, tagName=溶栓治疗), TagDto(tagId=15414, tagName=合理用药)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=12390, appHits=1673, showAppHits=14, pcHits=8003, showPcHits=4049, likes=151, shares=95, comments=14, approvalStatus=1, publishedTime=Sat Feb 16 16:52:48 CST 2019, publishedTimeString=2019-01-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sat Feb 16 16:52:48 CST 2019, updatedBy=null, updatedName=null, updatedTime=Thu Jan 04 03:13:11 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版))])
急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版)
下载请点击:
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2203657, encodeId=4833220365ea3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78ce9285278, createdName=ms4000001522389219, createdTime=Thu May 09 13:02:48 CST 2024, time=2024-05-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2113374, encodeId=7af621133e431, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc005113217, createdName=1461d1d4m80暂无昵称, createdTime=Tue Feb 07 10:22:28 CST 2023, time=2023-02-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2112905, encodeId=9b1421129059f, content=学习学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc005113217, createdName=1461d1d4m80暂无昵称, createdTime=Fri Feb 03 17:02:51 CST 2023, time=2023-02-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1079246, encodeId=2fb710e9246d1, content=111学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11036147068, createdName=ms3000001040135530, createdTime=Sun Dec 12 12:48:07 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950896, encodeId=7db19508964a, content=学习使人进步, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/fed1c69edef040aa845e61835a8d1382/53e965c9bdde4992a6e934a143e0aef7.jpg, createdBy=686b5468799, createdName=ms8000001914536834, createdTime=Thu Mar 25 01:12:37 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2024-05-09 ms4000001522389219 来自河北省

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2203657, encodeId=4833220365ea3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78ce9285278, createdName=ms4000001522389219, createdTime=Thu May 09 13:02:48 CST 2024, time=2024-05-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2113374, encodeId=7af621133e431, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc005113217, createdName=1461d1d4m80暂无昵称, createdTime=Tue Feb 07 10:22:28 CST 2023, time=2023-02-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2112905, encodeId=9b1421129059f, content=学习学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc005113217, createdName=1461d1d4m80暂无昵称, createdTime=Fri Feb 03 17:02:51 CST 2023, time=2023-02-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1079246, encodeId=2fb710e9246d1, content=111学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11036147068, createdName=ms3000001040135530, createdTime=Sun Dec 12 12:48:07 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950896, encodeId=7db19508964a, content=学习使人进步, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/fed1c69edef040aa845e61835a8d1382/53e965c9bdde4992a6e934a143e0aef7.jpg, createdBy=686b5468799, createdName=ms8000001914536834, createdTime=Thu Mar 25 01:12:37 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2023-02-07 1461d1d4m80暂无昵称 来自湖北省

    不错不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2203657, encodeId=4833220365ea3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78ce9285278, createdName=ms4000001522389219, createdTime=Thu May 09 13:02:48 CST 2024, time=2024-05-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2113374, encodeId=7af621133e431, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc005113217, createdName=1461d1d4m80暂无昵称, createdTime=Tue Feb 07 10:22:28 CST 2023, time=2023-02-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2112905, encodeId=9b1421129059f, content=学习学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc005113217, createdName=1461d1d4m80暂无昵称, createdTime=Fri Feb 03 17:02:51 CST 2023, time=2023-02-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1079246, encodeId=2fb710e9246d1, content=111学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11036147068, createdName=ms3000001040135530, createdTime=Sun Dec 12 12:48:07 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950896, encodeId=7db19508964a, content=学习使人进步, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/fed1c69edef040aa845e61835a8d1382/53e965c9bdde4992a6e934a143e0aef7.jpg, createdBy=686b5468799, createdName=ms8000001914536834, createdTime=Thu Mar 25 01:12:37 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2023-02-03 1461d1d4m80暂无昵称 来自湖北省

    学习学习!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2203657, encodeId=4833220365ea3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78ce9285278, createdName=ms4000001522389219, createdTime=Thu May 09 13:02:48 CST 2024, time=2024-05-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2113374, encodeId=7af621133e431, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc005113217, createdName=1461d1d4m80暂无昵称, createdTime=Tue Feb 07 10:22:28 CST 2023, time=2023-02-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2112905, encodeId=9b1421129059f, content=学习学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc005113217, createdName=1461d1d4m80暂无昵称, createdTime=Fri Feb 03 17:02:51 CST 2023, time=2023-02-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1079246, encodeId=2fb710e9246d1, content=111学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11036147068, createdName=ms3000001040135530, createdTime=Sun Dec 12 12:48:07 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950896, encodeId=7db19508964a, content=学习使人进步, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/fed1c69edef040aa845e61835a8d1382/53e965c9bdde4992a6e934a143e0aef7.jpg, createdBy=686b5468799, createdName=ms8000001914536834, createdTime=Thu Mar 25 01:12:37 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2021-12-12 ms3000001040135530

    111学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2203657, encodeId=4833220365ea3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78ce9285278, createdName=ms4000001522389219, createdTime=Thu May 09 13:02:48 CST 2024, time=2024-05-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2113374, encodeId=7af621133e431, content=不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc005113217, createdName=1461d1d4m80暂无昵称, createdTime=Tue Feb 07 10:22:28 CST 2023, time=2023-02-07, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2112905, encodeId=9b1421129059f, content=学习学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc005113217, createdName=1461d1d4m80暂无昵称, createdTime=Fri Feb 03 17:02:51 CST 2023, time=2023-02-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1079246, encodeId=2fb710e9246d1, content=111学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11036147068, createdName=ms3000001040135530, createdTime=Sun Dec 12 12:48:07 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950896, encodeId=7db19508964a, content=学习使人进步, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/fed1c69edef040aa845e61835a8d1382/53e965c9bdde4992a6e934a143e0aef7.jpg, createdBy=686b5468799, createdName=ms8000001914536834, createdTime=Thu Mar 25 01:12:37 CST 2021, time=2021-03-25, status=1, ipAttribution=)]
    2021-03-25 ms8000001914536834

    学习使人进步

    0

Baidu
map
Baidu
map
Baidu
map